Kymera Therapeutics (KYMR) Insider Booth Sells $14M of Stock

Booth's Significant Sale

On June 24, 2026, Bruce Booth sold 134,720 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) for approximately $13.5 million. The shares were sold at an average price of $100.51 each. This transaction was part of a planned selling strategy.

Insider Buying and Selling at Kymera Therapeutics, Inc.

This recent sale adds to Booth's previous transactions. Just a day earlier, on June 23, he sold 1,408 shares for about $140,772. On June 22, he sold 278,128 shares at an average price of $99.12, totaling around $27.6 million. Furthermore, on June 18, Booth sold 115,056 shares for about $10.5 million. These planned sales indicate Booth's strategy to adjust his holdings in the company.

How Kymera Therapeutics, Inc. Stock Has Traded

Kymera Therapeutics' stock is currently trading at $116.46, close to its 52-week high of $130.05. The shares have shown resilience, especially with a market cap of around $9.68 billion. This performance comes as the company is working on various drug candidates in clinical stages, which could impact future valuations.

Analysts Set New Price Targets

Analysts have a positive outlook on Kymera Therapeutics. On October 9, 2026, Raymond James initiated coverage with an "Outperform" rating and a price target of $140. Citigroup maintained its "Buy" rating on October 5, raising its target to $150 from $135. Other firms like Stifel and Bank of America also maintain their "Buy" ratings with targets of $152 and $144, respectively. With 22 analysts providing insights, the consensus remains strong on the stock's potential.

What Kymera Therapeutics, Inc. Does

Kymera Therapeutics focuses on discovering and developing small molecule therapeutics that degrade disease-causing proteins. The company has several drug candidates in clinical trials aimed at treating various conditions, including atopic dermatitis and autoimmune diseases. This recent insider activity reflects ongoing changes in the company's leadership and strategic direction.

What to Watch at Kymera Therapeutics, Inc.

Investors should keep an eye on the upcoming earnings report scheduled for November 3, 2026. As the company continues its clinical trials, further updates and filings may also provide insights into its progress and potential market performance. Remember, the recent insider sales reflect past holdings and may not represent current positions or future intentions.